Bioprojet is a pharmaceutical laboratory focused on therapeutic innovation and medicine development. Founded in 1982, it was created to bridge fundamental research and pharmaceutical development and is headquartered in Paris, France.
The FDA has approved Harmony Biosciences' Wakix (pitolisant) for treating cataplexy in pediatric patients aged 6 years and older with narcolepsy, making it the first non-scheduled treatment for both pediatric and adult narcolepsy patients with or without cataplexy.
The FDA approved Harmony Biosciences' supplemental new drug application for WAKIX (pitolisant) to treat cataplexy in pediatric patients 6 years and older with narcolepsy, making it the first non-scheduled treatment for both pediatric and adult narcolepsy patients with or without cataplexy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07074002 |
Proof of Concept Study on BP1.4979 Effect on Essential Tremor |
RECRUITING | PHASE2 |
| NCT07047404 |
Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation |
RECRUITING | PHASE2 |
| NCT05953389 |
Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05240560 |
Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke |
TERMINATED | PHASE2 |
| NCT05118906 |
Pilot Study on BP1.4979 Effect on Binge Eating Disorders |
COMPLETED | PHASE2 |
| NCT03424824 |
Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Alcohol Use Disorder Treatment |
COMPLETED | PHASE2 |
| NCT03345953 |
Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome |
TERMINATED | PHASE2 |
| NCT03152123 |
Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users |
COMPLETED | PHASE1 |
| NCT02978651 |
Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness |
WITHDRAWN | PHASE3 |
| NCT02929342 |
Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Pitolisant in Healthy Male Volunteers |
COMPLETED | PHASE1 |
